门冬胰岛素30联合伏格列波糖治疗2型糖尿病临床疗效观察

Therapeutic observation of insulin Aspart 30 combined with Voglibose in treating type 2 diabetes mellitus

关键词:  门冬胰岛素30  伏格列波糖  2型糖尿病

Key words:  Insulin Aspart 30  Voglibose  type 2 diabetes mellitus

摘要:

目的　观察应用门冬胰岛素30联合伏格列波糖和单用门冬胰岛素30治疗2型糖尿病（T2DM）的疗效。　方法　将80例T2DM患者随机分为门冬胰岛素30组（对照组）和门冬胰岛素30联合伏格列波糖组（观察组），治疗2周后，比较两种治疗后血糖及日胰岛素用量情况，观察低血糖发生的次数。　结果　门冬胰岛素30联合伏格列波糖治疗后三餐后血糖分别为（8.39±1.88）mmol/L、（8.21±1.55）mmol/L、（8.12±1.65）mmol/L，单用门冬胰岛素30治疗后三餐后血糖分别为（9.70±1.71）mmol/L、（10.32±1.43）mmol/L、（9.88±1.54）mmol/L，两组比较差异有显著性意义（P<0.05）；对空腹血糖控制观察组与对照组比较差异无显著性意义（P>0.05）。观察组胰岛素日用量（35.0±9.5）U较对照组（46.5±10.2）U少，两组比较差异有显著性意义（P<0.05）；观察组低血糖发生2次，少于对照组的9次，两组比较差异有显著性意义（P<0.05）。　结论　应用门冬胰岛素30联合伏格列波糖口服治疗2型糖尿病可显著提高疗效，使胰岛素用量更少，低血糖事件发生更少，是一种安全、有效的治疗方案。

Abstract:

Objective　To observe the therapeutic effect of Insulin Aspart 30 combined with Voglibose in treating type 2 diabetes mellitus.　Methods　80 patients with type 2 diabetes mellitus were randomly divided into two groups. 40 patients in control group were treated with Insulin Aspart 30 and the other patients in observation group were treated with Insulin Aspart 30 combined with Voglibose, with a treatment course of 2 weeks for both groups. Fasting blood glucose(FBG), 2 hours postprandial blood glucose (2hPBG), daily dosage of insulin and incidence of hypoglycemia were detected after treatment.　Results　 After 2 weeks, the 2hPBG was (8.39±1.88)mmol/L,(8.21±1.55)mmol/L,(8.12±1.65)mmol/L respectively in observation group and (9.70±1.71) mmol/L, (10.32±1.43) mmol/L, (9.88±1.54)mmol/L respectively in control group. Insulin daily dosage was (35.0±9.5)U in observation group and (46.5±10.2)U in control group. There were 9 hypoglycemic events in control group and 2 in observation group. So the 2hPBG, insulin daily dosage and incidence of hypoglycemia between the two groups were statistically significant (P<0.05). There were no statistical difference in the FBG between the two groups (P>0.05). 　Conclusion　 Insulin Aspart 30 combined with Voglibose is proved to be a safe and effective therapy for type 2 diabetes mellitus with lower insulin dosage and incidence of hypoglycemia.